Pharmacyclics Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PHARMACYCLICS LLC, and when can generic versions of PHARMACYCLICS LLC drugs launch?
PHARMACYCLICS LLC has three approved drugs.
There are fifty-four US patents protecting PHARMACYCLICS LLC drugs.
There are three hundred and fifty patent family members on PHARMACYCLICS LLC drugs in forty-seven countries and thirty-four supplementary protection certificates in fifteen countries.
Summary for Pharmacyclics Llc
International Patents: | 350 |
US Patents: | 54 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 3 |
Patent Litigation for Pharmacyclics Llc: | See patent lawsuits for Pharmacyclics Llc |
Drugs and US Patents for Pharmacyclics Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | 8,008,309*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | DISCN | Yes | No | 8,754,091*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | 10,751,342*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for PHARMACYCLICS LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 140 mg and 560 mg | ➤ Subscribe | 2018-11-05 |
➤ Subscribe | Capsules | 70 mg | ➤ Subscribe | 2018-12-14 |
➤ Subscribe | Tablets | 280 mg and 420 mg | ➤ Subscribe | 2018-12-14 |
International Patents for Pharmacyclics Llc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2022201741 | ⤷ Try a Trial |
Uruguay | 34848 | ⤷ Try a Trial |
Slovenia | 2526771 | ⤷ Try a Trial |
Israel | 275459 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharmacyclics Llc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2201840 | 1590021-0 | Sweden | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023 |
2526934 | C20160038 00313 | Estonia | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 30.05.2016 |
2526934 | PA2016034 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIBAS ARBA FARMACISKAI PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2016)3293 20160526 |
2529621 | 122017000015 | Germany | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.